LEO Pharma Presents Data at 2024 Winter Clinical and Maui Derm Conferences
MADISON, N.J.--(BUSINESS WIRE)--Jan 12, 2024--
Source: valdostadailytimes.com
Andreas Wollenberg News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Andreas Wollenberg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Andreas Wollenberg Today - Breaking & Trending Today
Baricitinib Results in Swift Improvements Among 4 Signs of Atopic Dermatitis in EASI
This new data align with the acknowledged necessity for a disruption of the itch–scratch cycle in moderate-to-severe AD treatment among patients.
Source: hcplive.com
Kyowa Kirin Announces Three Abstracts and A Symposium at the European Academy of Dermatology and Venereology Congress 2023
/PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that post-hoc analysis data from the Phase 2b study of rocatinlimab (AMG 451/KHK4083), an...
Source: prnewswire.com
Almirall: Up to 73% of Atopic Dermatitis Patients Taking Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis
Almirall S.A. today announced results from a new secondary analysis from the Phase 3 clinical development program which showed patients receiving lebrikizumab who were assessed at 16 weeks... | May 1, 2023
Source: marketscreener.com
LEO Pharma A/S: LEO Pharma Announces European Commission Approval of Adtralza (tralokinumab) for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents
Adtralza, a biologic that targets and neutralizes the interleukin (IL)-13 cytokine1, is now approved in Europe for adolescents with moderate-to-severe atopic dermatitis.2 NOT FOR DISTRIBUTION
Source: finanznachrichten.de